Logo Logo

Publications by Saußele, Susanne

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Jump to: 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2006
Number of items: 24.

2017

Hehlmann, Rüdiger; Lauseker, Michael; Saußele, Susanne; Hochhaus, Andreas; Hasford, Joerg; Pfirrmann, Markus; Kolb, Hans-Jochem; Spiekermann, Karsten; Fabarius, Alice; Müller, M. C.; Proetel, Ulrike; Kohlbrenner, K.; Voskanyan, A.; Rinaldetti, S.; Seifarth, W.; Spieß, B.; Krause, S. W.; Neubauer, A.; Burchert, A.; Hossfeld, Dieter K.; Schafhausen, P.; Nerl, C.; Gratwohl, A.; Heim, D.; Baerlocher, Gabriela M.; Brümmendorf, Tim H.; Fuchs, R.; Haferlach, C.; Jeromin, S.; Schlegelberger, Brigitte; Balleisen, L.; Goebeler, M. C.; Hänel, M.; Ho, A.; Dengler, J.; Falge, C.; Kanz, L.; Kremers, S.; Kneba, M.; Stegelmann, F.; Köhne, C. A.; Lindemann, H. W.; Waller, C. F.; Pfreundschuh, Michael; Berdel, Wolfgang E.; Müller, L.; Edinger, M.; Mayer, J.; Beelen, D. W.; Bentz, M.; Link, H.; Hertenstein, Bernd; Wernli, Martin; Schlegel, F.; Schlag, R.; Wit, M. de; Trumper, L.; Hebart, H.; Hahn, M.; Thomalla, J.; Scheid, C.; Verbeek, W.; Eckart, M. J.; Gassmann, W.; Pezzutto, A.; Schenk, M.; Brossart, P.; Geer, T.; Bildat, S.; Schäfer, E. (2017): Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. In: Leukemia, Vol. 31, No. 11: pp. 2398-2406

2016

Pfirrmann, Markus; Baccarani, M.; Saußele, Susanne; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V. S.; Castagnetti, F.; Hasford, Joerg; Hehlmann, R.; Simonsson, B. (2016): Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. In: Leukemia, Vol. 30, No. 1: pp. 48-56

Miranda, M. B.; Lauseker, Michael; Kraus, M. P.; Proetel, U.; Hanfstein, B.; Fabarius, A.; Baerlocher, Gabriela M.; Heim, D.; Hossfeld, D. K.; Kolb, H. J.; Krause, S. W.; Nerl, C.; Brümmendorf, Tim H.; Verbeek, W.; Fauser, A. A.; Prummer, O.; Neben, K.; Hess, U.; Mahlberg, R.; Ploger, C.; Flasshove, M.; Rendenbach, B.; Hofmann, W. K.; Muller, M. C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg; Hehlmann, R.; Saußele, Susanne (2016): Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. In: Leukemia, Vol. 30, No. 6: pp. 1255-1262

Kossak-Roth, U.; Saußele, Susanne; Aul, C.; Büchner, T.; Dohner, H.; Dugas, Martin; Ehninger, G.; Ganser, A.; Giagounidis, A.; Gökbuget, Nicola; Griesshammer, M.; Hasford, Joerg; Heuser, M.; Hiddemann, Wolfgang; Hochhaus, A.; Hoelzer, D.; Niederwieser, D. W.; Reiter, A.; Röllig, C.; Hehlmann, R. (2016): Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL). In: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, Vol. 59, No. 4: pp. 444-453

Gratwohl, A.; Pfirrmann, Markus; Zander, A.; Kröger, N.; Beelen, D.; Novotny, J.; Nerl, C.; Scheid, C.; Spiekermann, Karsten; Mayer, J.; Sayer, H. G.; Falge, C.; Bunjes, D.; Döhner, H.; Ganser, A.; Schmidt-Wolf, I.; Schwerdtfeger, R.; Baurmann, H.; Kuse, R.; Schmitz, N.; Wehmeier, A.; Fischer, J. T.; Ho, A. D.; Wilhelm, M.; Goebeler, M. E.; Lindemann, H. W.; Bormann, M.; Hertenstein, B.; Schlimok, G.; Baerlocher, Gabriela M.; Aul, C.; Pfreundschuh, M.; Fabian, M.; Staib, P.; Edinger, M.; Schatz, M.; Fauser, A.; Arnold, R.; Kindler, T.; Wulf, G.; Rosselet, A.; Hellmann, A.; Schäfer, E.; Prümmer, O.; Schenk, M.; Hasford, Joerg; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Büsche, G.; Haferlach, C.; Schnittger, S.; Müller, M. C.; Reiter, A.; Berger, Ute; Saußele, Susanne; Hochhaus, A.; Hehlmann, R. (2016): Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. In: Leukemia, Vol. 30, No. 3: pp. 562-569

2015

Saußele, Susanne; Krauß, M. P.; Hehlmann, R.; Lauseker, Michael; Proetel, U.; Kalmanti, L.; Hanfstein, B.; Fabarius, A.; Kraemer, D.; Berdel, W. E.; Bentz, M.; Staib, P.; de Wit, M.; Wernli, M.; Zettl, F.; Hebart, H. F.; Hahn, M.; Heymanns, J.; Schmidt-Wolf, I.; Schmitz, N.; Eckart, M. J.; Gassmann, W.; Bartholomäus, A.; Pezzutto, A.; Oppliger Leibundgut, E.; Heim, D.; Krause, S. W.; Burchert, A.; Hofmann, W. K.; Hasford, Joerg; Hochhaus, A.; Pfirrmann, Markus; Müller, M. C. (2015): Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. In: Blood, Vol. 126, No. 1: pp. 42-49

Fabarius, A.; Kalmanti, L.; Dietz, C. T.; Lauseker, Michael; Rinaldetti, S.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Hanfstein, B.; Seifarth, W.; Hänel, M.; Köhne, C. H.; Lindemann, H. W.; Berdel, W. E.; Staib, P.; Müller, M. C.; Proetel, U.; Balleisen, L.; Goebeler, M. E.; Dengler, J.; Falge, C.; Kanz, L.; Burchert, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Brümmendorf, Tim H.; Edinger, M.; Hofmann, W. K.; Pfirrmann, Markus; Hasford, Joerg; Krause, S.; Hochhaus, A.; Saußele, Susanne; Hehlmann, R. (2015): Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. In: Annals of Hematology, Vol. 94, No. 12: pp. 2015-2024

Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Muller, M. C.; Dietz, C. T.; Heinrich, L.; Hanfstein, B.; Proetel, U.; Fabarius, A.; Krause, S. W.; Rinaldetti, S.; Dengler, J.; Falge, C.; Oppliger-Leibundgut, E.; Burchert, A.; Neubauer, A.; Kanz, L.; Stegelmann, F.; Pfreundschuh, M.; Spiekermann, Karsten; Scheid, C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2015): Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. In: Leukemia, Vol. 29, No. 5: pp. 1123-1132

2014

Lauseker, Michael; Hanfstein, Benjamin; Haferlach, Claudia; Schnittger, Susanne; Pfirrmann, Markus; Fabarius, Alice; Schlegelberger, Brigitte; Saußele, Susanne; Dietz, Christian T.; Erben, Philipp; Hehlmann, Rüdiger; Hasford, Joerg; Hochhaus, Andreas; Müller, Martin C. (November 2014): Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. In: Journal of cancer research and clinical oncology, Vol. 140, No. 11: pp. 1965-1969

Hehlmann, Rüdiger; Hasford, Joerg; Pfirrmann, Markus; Lauseker, Michael; Saußele, Susanne; Hochhaus, Andreas (September 2014): Reply to H. Kantarjian et al. In: Journal of Clinical Oncology, Vol. 32, No. 27, 3078-3078

Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C.; Hanfstein, Benjamin; Krause, Stefan W.; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; Pfirrmann, Markus; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Rüdiger; Saußele, Susanne (July 2014): Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. In: Annals of Hematology, Vol. 93, No. 7: pp. 1167-1176 [PDF, 985kB]

Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Proetel, U.; Muller, M. C.; Hanfstein, B.; Schreiber, A.; Fabarius, A.; Pfirrmann, Markus; Schnittger, S.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Krause, S. W.; Heim, D.; Nerl, C.; Hossfeld, D. K.; Kolb, H. J.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2014): Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. In: Annals of Hematology, Vol. 93, No. 1: pp. 71-80

Hehlmann, R.; Müller, M. C.; Lauseker, Michael; Hanfstein, B.; Fabarius, A.; Schreiber, A.; Proetel, U.; Pletsch, N.; Pfirrmann, Markus; Haferlach, C.; Schnittger, S.; Einsele, H.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Ehninger, G.; Heim, D.; Heimpel, H.; Nerl, C.; Krause, S. W.; Hossfeld, D. K.; Kolb, H. J.; Hasford, Joerg; Saußele, Susanne; Hochhaus, A. (2014): Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. In: Journal of Clinical Oncology, Vol. 32, No. 5: pp. 415-423

2012

Saußele, Susanne; Pfirrmann, Markus (2012): Clinical Trials in Chronic Myeloid Leukemia. In: Current Hematologic Malignancy Reports, Vol. 7, No. 2: pp. 109-115

Hoffmann, Verena; Baccarani, M.; Hasford, Joerg; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus; Hehlmann, R. (2012): The EUTOS CML score aims to support clinical decision-making. In: Blood, Vol. 119, No. 12: pp. 2966-2967

Hanfstein, B.; Müller, M. C.; Hehlmann, R.; Erben, P.; Lauseker, Michael; Fabarius, A.; Schnittger, S.; Haferlach, C.; Göhring, G.; Proetel, U.; Kolb, H. J.; Krause, S. W.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Dengler, J.; Hänel, M.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Branford, S.; Hughes, T. P.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne; Hochhaus, A. (2012): Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). In: Leukemia, Vol. 26, No. 9: pp. 2096-2102

2011

Pfirrmann, Markus; Hochhaus, A.; Lauseker, Michael; Saußele, Susanne; Hehlmann, R.; Hasford, Joerg (2011): Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. In: Leukemia, Vol. 25, No. 9: pp. 1433-1438

Fabarius, A.; Leitner, A.; Hochhaus, A.; Müller, M. C.; Hanfstein, B.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Reiter, A.; Jung-Munkwitz, S.; Proetel, U.; Schwaab, J.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Ho, A. D.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Lauseker, Michael; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne; Hehlmann, R. (2011): Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. In: Blood, Vol. 118, No. 26: pp. 6760-6768

Hehlmann, R.; Grimwade, D.; Simonsson, B.; Apperley, J.; Baccarani, M.; Barbui, T.; Barosi, G.; Bassan, R.; Béné, M. C.; Berger, Ursula; Büchner, T.; Burnett, A.; Cross, N. C.; de Witte, T. J.; Dohner, H.; Dombret, H.; Einsele, H.; Engelich, G.; Foa, R.; Fonatsch, C.; Gökbuget, Nicola; Gluckman, E.; Gratwohl, A.; Guilhot, F.; Haferlach, C.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hochhaus, A.; Hoelzer, D.; Kiladjian, J. J.; Labar, B.; Ljungman, P.; Mansmann, Ulrich; Niederwieser, D. W.; Ossenkoppele, G.; Ribera, J. M.; Rieder, H.; Serve, H.; Schrotz-King, P.; Sanz, M. A.; Saußele, Susanne (2011): The European LeukemiaNet: achievements and perspectives. In: Haematologica, Vol. 96, No. 1: pp. 156-162

Hehlmann, R.; Lauseker, Michael; Jung-Munkwitz, S.; Leitner, A.; Müller, M. C.; Pletsch, N.; Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; Hänel, M.; Pfirrmann, Markus; Krause, S. W.; Nerl, C.; Pralle, H.; Gratwohl, A.; Hossfeld, D. K.; Hasford, Joerg; Hochhaus, A.; Saußele, Susanne (2011): Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. In: Journal of Clinical Oncology, Vol. 29, No. 12: pp. 1634-1642

Hasford, Joerg; Baccarani, M.; Hoffmann, Verena; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus; Hehlmann, R. (2011): Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. In: Blood, Vol. 118, No. 3: pp. 686-692

2010

Saußele, Susanne; Lauseker, Michael; Gratwohl, A.; Beelen, D. W.; Bunjes, D.; Schwerdtfeger, R.; Kolb, H. J.; Ho, A. D.; Falge, C.; Holler, E.; Schlimok, G.; Zander, A. R.; Arnold, R.; Kanz, L.; Dengler, R.; Haferlach, C.; Schlegelberger, B.; Pfirrmann, Markus; Müller, M. C.; Schnittger, S.; Leitner, A.; Pletsch, N.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2010): Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. In: Blood, Vol. 115, No. 10: pp. 1880-1885

2009

Rohrbacher, M.; Berger, Ursula; Hochhaus, A.; Metzgeroth, G.; Adam, K.; Lahaye, T.; Saußele, Susanne; Muller, M. C.; Hasford, Joerg; Heimpel, H.; Hehlmann, R. (2009): Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. In: Leukemia, Vol. 23, No. 3: pp. 602-604

2006

Saußele, Susanne; Adam, K.; Hochhaus, A.; Béné, M. C.; Büchner, T.; Burnett, A.; Finazzi, G.; Fonatsch, C.; Gluckman, E.; Gökbuget, Nicola; Grimwade, D. J.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hoelzer, D.; Ljungman, P.; Niederwieser, D. W.; Serve, H.; Simonsson, B.; de Witte, T. J.; Hehlmann, R. (2006): Klinische Forschung im „European LeukemiaNet”. In: Deutsche Medizinische Wochenschrift - DMW, Vol. 131, No. 43: pp. 2423-2426

This list was generated on Sun Jul 3 22:13:21 2022 CEST.